Impact of salvage chemotherapy after immune checkpoint inhibitor for recurrent or metastatic head and neck cancer-Reference-Cited by-同舟云学术

Impact of salvage chemotherapy after immune checkpoint inhibitor for recurrent or metastatic head and neck cancer

Published:2024-01-16 Issue:8 Volume:46 Page:1855-1864
ISSN:1043-3074
Container-title:Head & Neck
language:en
Short-container-title:Head & Neck

Author:

Matoba Takuma¹^ORCID,Minohara Kiyoshi¹,Kawakita Daisuke¹,Sawabe Michi²,Takano Gaku³,Oguri Keisuke⁴,Murashima Akihiro¹,Iwaki Sho¹^ORCID,Tsuge Hiroshi¹,Imaizumi Sae⁵,Hojo Wataru⁴,Kondo Ayano¹,Tsukamoto Koji⁶,Iwasaki Shinichi¹

Affiliation:

1. Department of Otorhinolaryngology, Head and Neck Surgery Nagoya City University Graduate School of Medical Sciences Nagoya Japan

2. Department of Otorhinolaryngology Toyota Kosei Hospital Toyota Japan

3. Department of Otorhinolaryngology Nagoya City University West Medical Center Nagoya Japan

4. Department of Otorhinolaryngology Anjo Kosei Hospital Anjo Japan

5. Department of Head and Neck Surgery The Cancer Institute Hospital of the Japanese Foundation for Cancer Research Tokyo Japan

6. Department of Head and Neck Surgery Aichi Cancer Center Hospital Nagoya Japan

Abstract

AbstractBackgroundIt is unclear witch regimen is optimal as salvage chemotherapy (SCT) after immune checkpoint inhibitor (ICI) monotherapy for recurrent or metastatic head and neck cancer (RM‐HNC).MethodsThis study enrolled 109 patients. Overall survival (OS) and progression‐free survival 2 (PFS2) were compared between patients stratified by SCT regimen.ResultsOf the 109 patients, 55 underwent SCT after the failure of ICI monotherapy. The OS of these 55 patients was longer than that of patients who did not undergo SCT. The OS and PFS2 were similar between patients treated with paclitaxel (PTX) and cetuximab (Cmab) combination and those treated with PTX monotherapy. The occurrence of irAEs did not impact PFS2 nor OS.ConclusionsSCT can improve the survival outcomes of patients with RM‐HNC. In addition to PTX and Cmab, PTX monotherapy is also considered an effective SCT regimen. SCT is effective regardless of the presence or absence of irAEs.

Funder

Japan Society for the Promotion of Science

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hed.27643

Reference25 articles.

1. The world cancer patient population (WCPP): An updated standard for international comparisons of population-based survival

2. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

3. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

4. Salvage Chemotherapy After Nivolumab for Recurrent or Metastatic Head and Neck Carcinoma